This study aims to evaluate the safety and efficacy of the umbilical cord blood mononuclear cells (UCB-MNCs) therapy for radiation-induced lung injuryr (RILI) by observing factors related to the therapeutic effect and adverse reactions of UCB-MNCs in treating RILI .
Ages 18-75 years,with no restriction on gender;
History of chest radiotherapy;
Diagnosed with grade 2-3 radiation-induced lung injury according to CTCAE 4.0 classification criteria in "Diagnosis and Treatment of Radiation-induced Lung Injury";
Inadequate response to conventional treatment for two weeks, with no relief or progressive worsening of symptoms;
Severe cardiac insufficiency (such as NYHA class III or IV), uncontrolled hypertension (systolic blood pressure ≥160mmHg or diastolic blood pressure ≥110mmHg);
Positive for hepatitis B, hepatitis C, human immunodeficiency virus (HIV), or syphilis;
ECOG score ≥2;
Currently participating in or participated in other clinical trials within 4 weeks;